ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim and Hanmi Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boehringer IngelheimHanmi Pharmaceutical
studies on the registry2,305191
open to participants now6112
phase 3 studies under way283
reach primary completion within a year458
programswith a study of their own in two years45+21 named only12

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoehringer IngelheimHanmi Pharmaceutical
Phase 1

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%

Hanmi Pharmaceutical: 4 of its 12 programs at phase 1

  1. HIP2503phase 1
  2. HM17321phase 1
  3. IL-2 Mutein/Fc Fusion Protein HM16390phase 1
  4. RLD2606phase 1
33%
Phase 2

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%

Hanmi Pharmaceutical: 3 of its 12 programs at phase 2

  1. belvarafenibphase 2
  2. HM15275phase 2
  3. cobimetinibphase 2
25%
Phase 3

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%

Hanmi Pharmaceutical: 5 of its 12 programs at phase 3

  1. efpeglenatidephase 3
  2. HCP1306phase 3
  3. HCP1803-4phase 3
  4. hip2602phase 3
  5. hpp2602-2phase 3
42%
Approved, new studies

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
Hanmi Pharmaceutical6 readouts · 3 phase 3··

Hanmi Pharmaceutical, Jan ’27: 1 program whose next study reaches primary completion

  1. HM15275phase 2 · Jan 0 · NCT07205900

Hanmi Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. RLD2606phase 1 · Feb 5 · NCT07939087

Hanmi Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. HM17321phase 1 · Mar 0 · NCT07219589
·····

Hanmi Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. hip2602phase 3 · Sep 0 · NCT07899073
  2. hpp2602-2phase 3 · Sep 0 · NCT07899073

Hanmi Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HCP1803-4phase 3 · Oct 30 · NCT07660796
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Hanmi Pharmaceutical

New programs 3

  • RLD2606phase 1 · first study · Nov 10
  • hip2602phase 3 · first study · Oct 20 · Erectile Dysfunction
  • hpp2602-2phase 3 · first study · Oct 20 · Erectile Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionBoehringer IngelheimHanmi Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Hanmi Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2both · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Hanmi Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Obesityboth · compare here

Boehringer Ingelheim in Obesity: 2 programs

  1. survodutidephase 3
  2. BI 3034701phase 2

Their studies: Boehringer Ingelheim’s studies of Obesity in search

Hanmi Pharmaceutical in Obesity: 3 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2
  3. HM17321phase 1

Their studies: Hanmi Pharmaceutical’s studies of Obesity in search

Colorectal Neoplasmsboth · compare here

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

Hanmi Pharmaceutical in Colorectal Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Colorectal Neoplasms in search

Melanomaboth · compare here

Boehringer Ingelheim in Melanoma: 1 program

  1. BI 3810944phase 1

Their studies: Boehringer Ingelheim’s studies of Melanoma in search

Hanmi Pharmaceutical in Melanoma: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Melanoma in search

Neoplasmsboth · compare here

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

Hanmi Pharmaceutical in Neoplasms: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasms in search

Neoplasm Metastasisboth · compare here

Boehringer Ingelheim in Neoplasm Metastasis: 1 program

  1. zongertinibphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasm Metastasis in search

Hanmi Pharmaceutical in Neoplasm Metastasis: 1 program

  1. belvarafenibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasm Metastasis in search

Ovarian Neoplasmsboth · compare here

Boehringer Ingelheim in Ovarian Neoplasms: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Ovarian Neoplasms in search

Hanmi Pharmaceutical in Ovarian Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Ovarian Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBoehringer IngelheimHanmi Pharmaceutical
GLP1Rsurvodutide, BI 3034701efpeglenatiderule
A target, or a pathogen for a vaccine, known for: Boehringer Ingelheim 24 of 45 · Hanmi Pharmaceutical 5 of 12 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21).